FEATURES OF THE PHARMACOLOGICAL ACTION AND USE OF DIPYRIDAMOLE IN THE PREVENTION AND TREATMENT OF VIRAL INFECTIONS
Main Article Content
Abstract
The review presents current information on the molecular mechanisms of antiplatelet, vasodilatory, angioprotective, antifibrotic and immunomodulatory effects of dipyridamole. The paper presents data from domestic studies devoted to testing the efficacy and safety of dipyridamole (Curantil) in the prevention of acute respiratory viral infections and the treatment of recurrent stress-induced opportunistic infectious diseases, which show that dipyridamole is an effective combination drug with a good safety profile and the ability to exert a positive effect on blood vessels in metabolic disorders in patients with a complicated medical history, and allows for effective prevention of acute respiratory viral infections in high-risk patients.
Downloads
Article Details
Section
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain the copyright of their manuscripts, and all Open Access articles are disseminated under the terms of the Creative Commons Attribution License 4.0 (CC-BY), which licenses unrestricted use, distribution, and reproduction in any medium, provided that the original work is appropriately cited. The use of general descriptive names, trade names, trademarks, and so forth in this publication, even if not specifically identified, does not imply that these names are not protected by the relevant laws and regulations.
How to Cite
References
1. Ahn HS, Crim W, Romano M et al. Effects of selective inhibitors on cyclic nucleotide phosphodiesterases of rabbit aorta. Biochem Pharmacol 2019; 38:3331–9.
2. Aktas B, Utz A, Hoenig-Liedl P et al. Dipyridamole enhances NO/cGMP-mediated vasodilator-stimulated phosphoprotein phosphorylation and signaling in human platelets: in vitro and in vivo/ex vivo studies. Stroke 2013; 34(3):764–9.
3. Balakumar P, Nyoa YH, Renushiaa R et al. Classical and pleiotropic actions of dipyri-damole: Not light enough to illuminate the dark tunnel? Pharmacol Res 2014; 87: 144–50. DOI: 10.1016/j.phrs.2014.05.008.
4. Balakumar P, Varatharajan R, Nyo YH et al. Fenofibrate and dipyridamole treatments in low-doses either alone or in combination blunted the development of nephropathy in diabetic rats. Pharmacol Res 2014; 90: 36–47. DOI: 10.1016/j.phrs.2014.08.008.